In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Fondazione licenses rare genetic disease agents to Glaxo

12 Apr 2018

Executive Summary

Fondazione Telethon (Italian nonprofit organization that supports genetic disease research) and the Fondazione San Raffaele del Monte Tabor (scientific institute) have granted GlaxoSmithKline PLC exclusive worldwide rights to their Phase I/II gene therapeutic for adenosine deaminase deficiency-severe combined immune deficiency (ADA-SCID; also known as the bubble boy syndrome).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By